Global initiative for chronic obstructive lung disease for chronic obstructive pulmonary disease: GOLD opportunity for lung disorders

被引:19
作者
Minas, M [1 ]
Dimitropoulos, K [1 ]
Pastaka, C [1 ]
Papadopoulos, D [1 ]
Markoulis, N [1 ]
Gourgoulianis, KI [1 ]
机构
[1] Univ Thessaly, Sch Med, Dept Pulm, Larisa, Greece
关键词
asthma; COPD; GOLD;
D O I
10.1016/j.ypmed.2004.06.010
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. The purpose of this study was to assess the agreement of asthma and chronic obstructive pulmonary disease (COPD) treatment prescribed by physicians and pulmonologists in comparison to asthma and COPD guidelines and the need of the implementation of COPD guidelines in primary health care physicians. Methods. Eighty-three asthma patients and 100 COPD patients were chosen and classified in relation to the agreement of their treatment prescribed by a health care physician and that mentioned by global initiative for chronic obstructive lung disease (GOLD) The COPD patients were classified according to their stage of the disease too. Results. Both pulmonologists and primary health care physicians manage asthma patients following asthma guidelines, while great proportion of COPD patients are undertreated by primary health care physicians. The proportion of undertreated COPD patients is decreased as the stage of disease is progressing. Conclusions. COPD patients mainly are undertreated by primary health care physicians when they are in the primary stages of the disease. The overtreatment of some patients consists of high doses of inhaled steroids prescribed by both pulmonologists, and mainly, primary health care physicians. Therefore, it can be concluded that there is the need of the implementation of COPD guideline by primary health care physicians and the need of COPD patients to, be, diagnosed in early stages by performing spirometry. (C) 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved.
引用
收藏
页码:274 / 277
页数:4
相关论文
共 15 条
[1]  
*BRIT THOR SOC, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]
[2]  
CARVERLEY PM, 2000, AM J RESP CRIT CARE, V161, P342
[3]   Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: A multicenter, randomized, open-label trial [J].
Condemi, JJ .
CLINICAL THERAPEUTICS, 2001, 23 (09) :1529-1541
[4]   Detection of COPD in high-risk populations [J].
Gourgoulianis, KI ;
Hristou, K ;
Molyvdas, PA .
CHEST, 2002, 121 (05) :1721-1721
[5]   Prescription of medications by primary care physicians in the light of asthma guidelines [J].
Gourgoulianis, KI ;
Hamos, B ;
Christou, K ;
Rizopoulou, D ;
Efthimiou, A .
RESPIRATION, 1998, 65 (01) :18-20
[6]  
MACIVOR RA, 2001, CAN RESP J, V8, P153
[7]   Efficacy of salmeterol xinafoate in the treatment of COPD [J].
Mahler, DA ;
Donohue, JF ;
Barbee, RA ;
Goldman, MD ;
Gross, NJ ;
Wisniewski, ME ;
Yancey, SW ;
Zakes, BA ;
Rickard, KA ;
Anderson, WH .
CHEST, 1999, 115 (04) :957-965
[8]   INHALED DRUG CONSUMPTION AND ASTHMA MORTALITY IN GREECE [J].
MELISSINOS, CG ;
GOURGOULIANIS, K ;
ADAMIDIS, SC .
CHEST, 1995, 107 (06) :1771-1772
[9]  
*NAT I HLTH, 2001, NHLBWHO WORKSH REPOR
[10]  
*NIH, 2002, NHLBI WHO WORKSH